title: Body dysmorphic disorder.
abstract: The understanding of BDD and its treatment has expanded significantly in the past decade as controlled research has followed the leads from case reports and clinical experience. BDD is recognized as a severe, disabling disorder that is more common that had been assumed. Although BDD is still difficult to treat, success has been demonstrated for SRIs and CBT. Much remains to be discovered. To date, little is known about the causes and pathophysiology of BDD. Research that would illuminate these also would increase understanding of its relationship to other disorders, such as OCD, depression, and social phobia, and open up possibilities for prevention and new approaches to treatment. Investigations in brain imaging and genetics are underway. Research in pharmacotherapy and CBT, individually and combined, is needed to refine, extend, and optimize treatment.
authors.affiliation: Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA. andrea.allen@mssm.edu
authors.forename: A
authors.initials: A
authors.lastname: Allen
authors.forename: E
authors.initials: E
authors.lastname: Hollander
mesh_terms: D015928:Cognitive Behavioral Therapy / Q000379:methods; D015897:Comorbidity; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D013001:Somatoform Disorders / Q000175:diagnosis* / Q000453:epidemiology / Q000523:psychology / Q000628:therapy*
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors